Vertaling van "al risk of venous " (Frans → Nederlands) :

(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing
(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or

(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral
(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral contraceptives

(Lidegaard 2009) Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous
(Lidegaard 2009) Lidegaard Ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone

Risk of venous thromboembolism in users of oral contraceptives
Risk of venous thromboembolism in users of oral contraceptives containing

(van Hylckama 2009) van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral
(van Hylckama 2009) van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP et al. The venous thrombotic risk of oral contraceptives,

(Vasilakis-Scaramozza 2001) Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or
(Vasilakis-Scaramozza 2001) Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.

G. Lowe et P. Sandercock: Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?
G. Lowe en P. Sandercock: Prevention of venous thromboembolism after major orthopaedic surgery: is fondaparinux an advance?

H. Büller et M. Prins: Secondary prophylaxis with warfarin for venous thromboembolism (editorial).
H. Büller en M. Prins: Secondary prophylaxis with warfarin for venous thromboembolism (editorial).

Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.